© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Longeveron Inc. (LGVN) stock surged +0.66%, trading at $0.55 on NASDAQ, up from the previous close of $0.54. The stock opened at $0.50, fluctuating between $0.50 and $0.56 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Mar 02, 2026 | 0.50 | 0.56 | 0.50 | 0.55 | 227.71K |
| Feb 27, 2026 | 0.59 | 0.59 | 0.54 | 0.54 | 263.38K |
| Feb 26, 2026 | 0.55 | 0.59 | 0.53 | 0.58 | 1.08M |
| Feb 25, 2026 | 0.57 | 0.70 | 0.50 | 0.55 | 5.08M |
| Feb 24, 2026 | 0.57 | 0.58 | 0.55 | 0.58 | 38.36K |
| Feb 23, 2026 | 0.58 | 0.58 | 0.55 | 0.57 | 73.76K |
| Feb 20, 2026 | 0.56 | 0.58 | 0.55 | 0.58 | 47.06K |
| Feb 19, 2026 | 0.57 | 0.57 | 0.54 | 0.56 | 96.51K |
| Feb 18, 2026 | 0.53 | 0.56 | 0.53 | 0.56 | 50.23K |
| Feb 17, 2026 | 0.55 | 0.55 | 0.53 | 0.55 | 108.72K |
| Feb 13, 2026 | 0.53 | 0.55 | 0.53 | 0.54 | 131.34K |
| Feb 12, 2026 | 0.54 | 0.56 | 0.52 | 0.53 | 43.13K |
| Feb 11, 2026 | 0.56 | 0.57 | 0.53 | 0.54 | 105.63K |
| Feb 10, 2026 | 0.54 | 0.56 | 0.53 | 0.56 | 67.83K |
| Feb 09, 2026 | 0.51 | 0.55 | 0.51 | 0.54 | 101.86K |
| Feb 06, 2026 | 0.52 | 0.53 | 0.51 | 0.51 | 80.53K |
| Feb 05, 2026 | 0.56 | 0.56 | 0.50 | 0.51 | 305.85K |
| Feb 04, 2026 | 0.53 | 0.55 | 0.53 | 0.54 | 168.55K |
| Feb 03, 2026 | 0.54 | 0.57 | 0.53 | 0.55 | 117.63K |
| Feb 02, 2026 | 0.56 | 0.56 | 0.52 | 0.54 | 245.89K |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
| Employees | 25 |
| Beta | 0.2 |
| Sales or Revenue | $709.00K |
| 5Y Sales Change% | -0.757% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |